drugset / Trial / NCT04518306

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

NCT04518306

Phase 3 Completed 755 enrolled George Medicines PTY Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to placebo.

Timeline

Start
2021-06-14
Primary completion
2023-09-19
Completion
2023-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 1.25 mg Oral
Subject Amlodipine Other / unclassified 2.5 mg Oral
Subject Indapamide Small molecule 0.625 mg Oral
Subject Indapamide Small molecule 1.25 mg Oral
Subject Telmisartan Other / unclassified 10 mg Oral
Subject Telmisartan Other / unclassified 20 mg Oral

Indications